Urological tumors refer to malignancies occurring in any part of the urinary system. The most common types include prostate cancer, kidney cancer, and bladder cancer, as well as renal pelvic cancer, ureteral cancer, and the rarer urethral cancer.

Typical symptoms include painless hematuria, difficulty urinating or weakened urinary stream, flank pain, urinary frequency or urgency. Advanced cases may present with weight loss, fatigue, or symptoms resulting from metastasis such as bone pain, cough, or hepatomegaly.

The treatment of urological tumors is diverse and must be tailored to tumor type, stage, and individual patient characteristics, typically developed through a multidisciplinary decision-making process. Major treatment modalities include:

Surgery

The primary treatment for early-stage or localized tumors. Surgery can remove the tumor and, when feasible, preserve organ function while achieving curative outcomes.

Radiation Therapy

Used as an alternative or adjunct to surgery. Commonly applied in radical treatment of prostate cancer, bladder-preserving strategies for bladder cancer, and palliation for advanced urological malignancies.

Chemotherapy

Often used for advanced or metastatic disease. For example, systemic chemotherapy is common for bladder cancer, and some patients may receive intravesical chemotherapy after surgery to reduce recurrence risk.

Targeted Therapy

A major advancement in recent years, especially in kidney cancer, where targeted therapies are well established. They are also increasingly used for bladder cancer and other urological malignancies with actionable targets, helping to delay progression and improve survival.

Immunotherapy

Immune checkpoint inhibitors (e.g., PD-1/PD-L1 inhibitors) are widely used for advanced or relapsed kidney cancer, bladder cancer, and other urological tumors. By activating the patient’s immune system, immunotherapy can lead to long-term disease control or durable remission, significantly improving survival and quality of life.

Endocrine Therapy

A cornerstone treatment for prostate cancer. Hormonal therapy effectively controls tumor progression, alleviates symptoms, and is often combined with surgery, radiotherapy, or chemotherapy to enhance long-term outcomes and quality of life.

The GoBroad urologic oncology team is led by Professor Guo Jun, an internationally renowned expert. He founded China’s first medical oncology specialty focused on kidney cancer and has led or contributed to multiple national clinical guidelines, establishing the foundation for standardized diagnosis and treatment. Internationally, his team has achieved major breakthroughs, led globally innovative research and delivering the first-ever oral presentation by Chinese scholars at the ASCO GU annual meeting—bringing China’s voice to the world stage.

Over the years, Professor Guo has continuously promoted innovation in both clinical practice and scientific research, contributing to the approval of multiple novel therapies in China and ushering in a new era of “targeted therapy + immunotherapy” for advanced kidney cancer, enabling more patients to achieve long-term survival and improved quality of life.